Hims & Hers Health, Inc. (NYSE:HIMS) Stock Has Average Price Target of $32.43 According to Brokerages

Hims & Hers Health, Inc. (NYSE:HIMS) has received an average rating of “Hold” from the fifteen research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eleven have assigned a hold recommendation and three have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $32.43.

Several brokerages recently weighed in on HIMS. Zacks Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. JPMorgan Chase & Co. initiated coverage on shares of Hims & Hers Health in a report on Friday, September 11th. They set a “neutral” rating and a $32.00 target price for the company. Bank of America lifted their target price on shares of Hims & Hers Health from $30.00 to $32.00 and gave the stock a “neutral” rating in a report on Tuesday, August 11th. TD Cowen upped their target price on shares of Hims & Hers Health from $25.00 to $30.00 and gave the company a “hold” rating in a research report on Tuesday, August 11th. Finally, Barclays cut their price target on Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating on the stock in a research note on Friday, August 21st.

Hims & Hers Health Stock Performance

Shares of NYSE:HIMS opened at $29.36 on Thursday. The stock has a market capitalization of $6.85 billion, a P/E ratio of -46.60 and a beta of 2.44. Hims & Hers Health has a 1-year low of $13.74 and a 1-year high of $48.46. The company has a current ratio of 0.93, a quick ratio of 0.87 and a debt-to-equity ratio of 4.21. The business has a 50-day moving average price of $29.15 and a two-hundred day moving average price of $27.11.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). The business had revenue of $753.21 million for the quarter, compared to analyst estimates of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The business’s revenue for the quarter was up 38.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.17 earnings per share. Equities analysts predict that Hims & Hers Health will post -0.16 earnings per share for the current year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, COO Michael Chi sold 14,027 shares of the stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $28.39, for a total value of $398,226.53. Following the transaction, the chief operating officer owned 456,660 shares of the company’s stock, valued at approximately $12,964,577.40. This represents a 2.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Oluyemi Okupe sold 2,000 shares of the stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $29.70, for a total value of $59,400.00. Following the completion of the transaction, the chief financial officer directly owned 234,527 shares in the company, valued at $6,965,451.90. The trade was a 0.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 130,443 shares of company stock worth $3,731,426. 11.76% of the stock is owned by insiders.

Institutional Trading of Hims & Hers Health

A number of hedge funds have recently modified their holdings of the company. Versant Capital Management Inc raised its stake in Hims & Hers Health by 801.2% during the second quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock worth $26,000 after acquiring an additional 665 shares in the last quarter. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Hims & Hers Health by 70.0% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock worth $27,000 after acquiring an additional 319 shares during the last quarter. GK Wealth Management LLC acquired a new stake in shares of Hims & Hers Health in the 3rd quarter valued at approximately $37,000. Compass Financial Management LLC acquired a new stake in shares of Hims & Hers Health in the 2nd quarter valued at approximately $50,000. Finally, Bogart Wealth LLC grew its holdings in shares of Hims & Hers Health by 180.7% during the 1st quarter. Bogart Wealth LLC now owns 2,526 shares of the company’s stock valued at $52,000 after purchasing an additional 1,626 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: The Department of Health and Human Services reportedly said it would temporarily use “enforcement discretion” to allow compounding of six peptides. The decision could expand Hims & Hers’ treatment offerings and reduce near-term regulatory pressure on its compounded-medication business, supporting the stock’s move higher. HIMS stock jumps after HHS temporarily clears compounding of six peptides
• Positive Sentiment: The HHS action is being viewed as a potential relief for telehealth providers that rely on compounded therapies. However, the policy is temporary, so the longer-term commercial benefit remains dependent on future regulatory decisions. Hims & Hers jumped as HHS uses enforcement discretion to open peptide compounding
• Neutral Sentiment: Hims & Hers is seeking dismissal of a Federal Trade Commission and states’ data-privacy case. A successful dismissal could remove a legal risk, but the outcome is unresolved. Hims & Hers seeks dismissal of FTC and states’ data privacy case
• Negative Sentiment: Multiple law firms reiterated that investors have until November 2, 2026, to seek lead-plaintiff status in a securities class action covering purchases from August 4, 2025, through July 29, 2026. The case stems from allegations tied to the FTC’s complaint, including alleged business misconduct, privacy, and billing practices. These are allegations, not established findings, but the litigation creates reputational, financial, and management risks. HIMS class-action deadline alert
• Negative Sentiment: Investor commentary also highlights the possibility of a substantial further decline, underscoring continued volatility and uncertainty around HIMS’s legal exposure, regulatory outlook, and profitability. Can Hims & Hers stock fall 30%?

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides telehealth services through the Hims and Hers platforms. The company connects consumers with licensed healthcare providers through online consultations and offers access to prescription and over-the-counter products, as well as educational and wellness resources.

Its services address areas including sexual health, hair loss, skincare, mental health, weight management and primary care. Depending on the condition and eligibility requirements, customers may receive personalized treatment plans and have prescribed medications delivered directly to them.